Pyrvinium vs Placebo for Gastric Intestinal Metaplasia
REVerse Intestinal Metaplasia in the Stomach (REVISE)
Recruiting
Phase 2
Interventional Study
Gastric Intestinal Metaplasia
Gastric Precancer
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 32 (estimated)
- Sponsor
- Katherine Garman · Other
Who this trial is looking for
This trial is looking for adults over 18 with a specific stomach condition that has a higher risk of cancer. Participants will receive either the treatment Pyrvinium or a placebo, and will be monitored to see how their condition changes.
Are You a Good Fit for This Trial?
You may be able to join if
- I am over 18 years old
- I have been diagnosed with gastric intestinal metaplasia
- I have at least one high-risk feature for cancer
- I can provide informed consent
- I have had but do not currently have H. pylori infection
You may not be able to join if
- I have an active diagnosis of gastric cancer
- I am at high risk for bleeding complications
- I am pregnant
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is designed to test the use of Pyrvinium vs placebo as a treatment for gastric intestinal metaplasia with features associated with increased risk of cancer. Response will be determined by assessing the extent and quality of the gastric intestinal metaplasia before and after treatment.
A secondary aim will be to generate gastric organoids from patient-derived samples to test the effects…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults (including men, women, and non-binary individuals) over age 18 with known GIM with at least one high-risk feature (extensive vs limited, incomplete or mixed-type GIM, family history of stomach cancer),
* Ability to provide informed consent,
* Evidence of prior but not a…
Contacts